Skip to main content
Premium Trial:

Request an Annual Quote

BTIG Initiates Coverage of Fulgent Genetics

NEW YORK ­– Investment bank BTIG has initiated coverage of Fulgent Genetics with a Buy rating and a $20 price target.

In a research note on Thursday, BTIG analyst Sung Ji Nam wrote that Fulgent has shown growth over the past several years.

"We anticipate this strong growth momentum to continue over the next few years with FLGT's expanding product offerings and customer base," Nam wrote. "With the company's focus on operational efficiency, we believe FLGT has the cost structure to reach sustainable profitability relatively sooner than its peer group of molecular genetic testing service companies."

Based in Temple City, California, Fulgent offers clinical genetic testing using next-generation sequencing. The firm also has a consumer-oriented testing firm, Picture Genetics.

In morning trading on the Nasdaq, shares of Fulgent were up 4 percent at $16.70.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.